Oregon Health And Science University

Transcatheter aortic valve replacement among Medicare beneficiaries grew rapidly from 2014 to 2018 with an expansion in TAVR operators, but more than one-third of operators are performing fewer than 10 procedures per year, data show.

Ripretinib did not extend PFS compared with sunitinib for patients with advanced gastrointestinal stromal tumor who previously received imatinib, according to randomized phase 3 study results presented during the ASCO Plenary Series.

Bimekizumab demonstrates statistically significant improvement over placebo in the proportion of patients achieving Assessment of Spondyloarthritis International Society 40 response at week 16, according to interim results released by UCB.

Nearly all responders to a 26-week course of oral octreotide maintained a biochemical response and symptomatic control of acromegaly at 62 weeks, according to data from the MPOWERED trial.

Few randomized clinical trials support using repository corticotropin injection for most FDA-approved indications, including rheumatoid arthritis, ankylosing spondylitis, lupus, optic neuritis and nephrotic syndrome, according to researchers.

The FDA approved the steroidogenesis inhibitor levoketoconazole for adults with Cushing’s syndrome for whom surgery is not an option or has not been curative, according to an industry press release.

Early clinical trials for the first chimeric antigen receptor T-cell therapies mandated recipients receive rigorous post-treatment monitoring, often requiring inpatient admittance lasting anywhere from 2 to 4 weeks.

Rheumatologists who prescribe hydroxychloroquine or chloroquine should be aware of their potential cardiac toxicity, especially in high-risk patients with rheumatic disease, according to an American College of Rheumatology white paper.

At 30 days, a group of 15 patients who underwent transfemoral transcatheter mitral valve replacement for moderate to severe mitral regurgitation had no deaths, strokes, reinterventions or new pacemakers, a speaker reported.

An updated guideline for the treatment of Cushing’s disease focuses on new therapeutic options and an algorithm for screening and diagnosis, along with best practices for managing disease recurrence.